KRAS and colorectal carcinoma: For example, as early as 2009, researchers were estimating that routine testing for KRAS mutations in CRC patients would save approximately $740 million a year, whilst more recently, Vijayaraghavan et al. [121] have estimated that KRAS mutation testing saves $7,500–$12,400 per patient in the USA and €3,900–€9,600 per patient in Germany.